CTOs on the Move

Elucida Oncology

www.elucidaoncology.com

 
Elucida Oncology, Inc., is a clinical development stage company based on proprietary ultra-small C-Dot technology to find, see and treat an array of solid tumor cancers. Developed and clinically translated by Memorial Sloan-Kettering Cancer Center and Cornell University, C-Dots have published human safety and tumor-specific clinical data. Elucida Oncology is currently progressing through a broad clinical trial program while continuing to drive a future portfolio through ongoing innovation.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Elucida Oncology raised $44M on 01/12/2021

Similar Companies

Sienna Biopharmaceuticals

Sienna Biopharmaceuticals is focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes, and physicians’ practice of medicine.

jCyte

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.

Demetrix

Nature is a rich source of ingredients. Inconsistent quality and supply, along with inaccessibility of rare substances, mean it`s not always an ideal source to meet the world`s needs.

Tri State Surgical Supply

Tri State Surgical Supply is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuron Therapeutics

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company`s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders. For more information about Neurona visit our website.